efalizumab (Raptiva)
Jump to navigation
Jump to search
Introduction
Tradename: Raptiva (FDA approved 2003) (withdrawn from US market June 2009 due to risk of PML)
Indications
- moderate to severe plaque psoriasis
Dosage
injection SQ weekly (cost $14,000/year)
Monitor
platelet count monthly for 1st 3 months, then every 3 months
Adverse effects
- thrombocytopenia
- complications of immunosuppression
- infection[4]
- necrotizing fasciitis
- tuberculous pneumonia
- bacterial sepsis with seeding of distant sites
- severe pneumonia with neutropenia
- worsening of infection (e.g. cellulitis, pneumonia) despite antimicrobial treatment
- viral meningitis
- invasive fungal disease
- progressive multifocal leukoencephalopathy
- malignancy
- infection[4]
- immune-mediated hemolytic anemia[4]
- life-threatening infections, including[5][7]
- drug adverse effects of immunosuppressive agents
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
- monoclonal antibody: blocks T-cells
More general terms
References
- ↑ Prescriber's Letter 10(12):69 2003
- ↑ Leonardi CL, Efalizumab: an overview. N Engl 349:2014, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12894132
- ↑ Journal Watch 24(1):11, 2004 Lebwohl M et al, N Engl J Med 349:2004, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14627785 Leonardi CL et al, N Engl J Med 349:2014, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14627786
- ↑ 4.0 4.1 4.2 FDA Medwatch http://www.fda.gov/medwatch/safety/2005/safety05.htm#Raptiva
- ↑ 5.0 5.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Raptiva
- ↑ FDA patient safety news http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=83#1
- ↑ 7.0 7.1 7.2 FDA MedWatch http://www.fda.gov/medwatch/safety/2009/safety09.htm#Raptiva